Corium International Inc

Corium International — Investor Presentation (January 2017)

33 slides from Corium International's investor presentation, Jan 9, 2017

  1. Slide 1: Corium Investor Update January 2017

    Corium Investor Update January 2017

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Transdermal solutions that transform care

    Transdermal solutions that transform care Leading Transdermal Product Innovation Vision Building a robust pipeline of novel CNS products Streamlined path for donepezil Alzheimer’s program Approach Lead Product 10+ years of development & manufacturing expertise Core Strengths

  4. Slide 4: Proven Leadership Team

    Proven Leadership Team Peter Staple Chief Executive Officer Robert Breuil Chief Financial Officer Joseph Sarret, MD Chief Business Officer Bobby Singh, PhD Chief Technology Officer Tim Sweemer, CPA Chief Accounting Officer Dan Arsulowicz VP Operations Grand Rapids Christina Dickerson VP Corporate De

  5. Slide 5: Advancing Pipeline with Near-term Milestones

    CY 2017 CY 2018 1H 2H 1H 2H Results of Pilot BE study on donepezil Pivotal BE study on donepezil PK results on optimized memantine Pilot BE study on memantine Twirla resubmission* Twirla NDA response* Advancing Pipeline with Near-term Milestones 3Q CY 2017 1H CY 2017 Data 1H CY 2017 Anticipating 6-M

  6. Slide 6: Enabling Technology: Corplex

    Enabling Technology: Corplex™ Novel combinations of pressure-sensitive and bioadhesive polymers Can adhere to both dry and wet surfaces Sustained drug delivery up to 7 days Load large amounts of drug/liquid Uniquely well-suited for poorly soluble drugs Has enabled first-in-patch applications

  7. Slide 7: Blending Hydrophilic and Hydrophobic Polymers

    Hydrophobic domains provide: Robust adhesive capability Hydrophilic domains provide: Capability to hold liquids with solubilized drug Excellent moisture handling capability Separation of liquid from adhesive Exceptional flexibility and conformability Enhanced stability, loading, and delivery Blendin

  8. Slide 8: Our Focus: CNS Diseases

    Our Focus: CNS Diseases Rationale for transdermal CNS Sustained and consistent drug effect Improve compliance Reduce side effects, especially GI-related Reversibility of patch vs. injectables Alzheimer’s Parkinson’s Schizophrenia Depression Anxiety Bipolar Disorder Epilepsy >5 million people in US h

  9. Slide 9: A Transformational Market Opportunity

    Exelon Daily Patch A Transformational Market Opportunity 9% 51% 39% $0.5 $4.2 $2.3 $1.1 Rivastigmine (Exelon®) Donepezil (Aricept®) Memantine (Namenda®) 2015 U.S. TRx Share Peak WW Oral Sales (Billions) Peak WW Patch Sales (Billions) CNS Specialty Pharma Opportunity Alzheimer’s Treatments Sources: I

  10. Slide 10: Donepezil and Memantine are Dominant Therapies

    Donepezil and Memantine are Dominant Therapies * Major Markets include US, Japan, Germany, UK, France, Spain and Italy **Pre-disease indicates 1-2 years prior Source: DR/Decision Resources, LLC, 2014 market data for all formulations Major Market* Patient Share Donepezil is dominant agent throughout

  11. Slide 11: Once-weekly Patch Benefits

    Once-weekly Patch Benefits Patients and caregivers have challenges with daily medication Difficulties/willingness to swallow pills increase with disease progression Patches offer the potential for lower incidence of GI adverse events AChEI adherence is correlated with reductions in acute healthcare

  12. Slide 12: Physician Intent to Prescribe is High

    Physician Intent to Prescribe is High Q: How likely are you to prescribe Corplex Donepezil to your Alzheimer’s patients? Probably (42%) Definitely (31%) Undecided Probably not (5%) Definitely not (1%) Likely Not likely U.S. survey of 225 physicians; 150 family practitioners and 75 neuros Assumes $40

  13. Slide 13: Caregiver Interest and Intent to Fill is High

    Intent to Fill Prescription Q: “Assume the doctor for the person you care for wrote that person a prescription for a one-month supply of PRODUCT D*. How likely is it that the PRODUCT D prescription would be filled for the person you care for?” 87% 87% 87% 94% (n=281) (n=158) (n=175) (n=50) Survey of

  14. Slide 14: Payer Approach: Consistent with Exelon Patch

    Payer Approach: Consistent with Exelon Patch Interviews with formulary decision makers at 12 U.S. payers* Level of coverage similar to branded Exelon patch and Namenda XR > 50% of plans would require minimal utilization management At least one generic prescription in past 180 days 3 of 8 Medicaid pl

  15. Slide 15: Validated Pricing for Branded Transdermal Products

    Validated Pricing for Branded Transdermal Products 2015 TRx* in U.S. for Acetylcholinesterase Inhibitor (AChEI) Class = 13.3M Each 1% in U.S. market share = 133K TRx Each 1% of branded U.S. AChEI market = $94M * Source: IMS. TRx = Total Prescriptions (new plus refills) On average, each TRx represent

  16. Slide 16: Memantine Market Research Results

    Memantine Market Research Results very similar to donepezil 62% of physicians likely to prescribe* (vs. 73% for donepezil) 77% of caregivers intend to fill prescriptions† (vs. 87% for donepezil) Payers indicate coverage for memantine the same as for donepezil‡ No payer objected to covering both prod

  17. Slide 17: Positive FDA Guidance on Bioequivalence Pathway

    Positive FDA Guidance on Bioequivalence Pathway FDA agreed with proposed BE approach for both drugs Written responses confirmed clinical study designs and regulatory pathway Guidance based on Phase 1 PK profiles generated in 1H 2016 Key factor is long half life: donepezil = 70 hours; memantine = 60-

  18. Slide 18: Corium's Bioequivalence Pathway Experience

    Corium’s Bioequivalence Pathway Experience Therapeutic Area Demonstrated Bioequivalence Pain 41 subjects Hypertension 28 subjects Urology 39 subjects Motion Sickness 37 subjects Women’s Health 37 subjects A proven BE track record with different types of molecules

  19. Slide 19: Pilot Study Design and Timing

    Pilot Study Design and Timing Three period, three-treatment, randomized crossover study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 PK PK PK Cohort 1 Screening 5mg 10mg Aricept Oral Washout 5mg 10mg Patch B Washout 5mg 10mg Patch A Follow-Up PK PK PK Cohort 2 Screening

  20. Slide 20: Pilot Study Update (as of Week 13)

    Pilot Study Update (as of Week 13) Enrollment 60 subjects enrolled at start of study 56 completed Treatment Period 1 All 56 started Treatment Period 2 Steady state PK profiles Very consistent with projections Systemic safety Early signals of possible differentiation Skin tolerability Very good, cons

  21. Slide 21: Mean Projected Concentrations at Steady State

    Mean Projected* Concentrations at Steady State Projected* PK Profile from Phase 1 Data Corplex Donepezil QW Aricept PO QD (Day 7) AUCDay7 AUCtau,ss = 7 x AUCD7 AUC = AUC over dosage interval PO = Per oral QW = Once weekly QD = Once-daily Aricept Projected Daily PK * Projections based on one-week PK

  22. Slide 22: Observed PK Profiles from Pilot BE

    Observed PK Profiles from Pilot BE* Cmax,ss Oral PK measured only on Day 7 Oral Aricept Projected Daily PK * Preliminary parallel data from first 5-week treatment period of pilot study (Dec 2016) Mean Observed Concentrations at Steady State 0 10 20 30 40 50 60 70 0 1 2 3 4 5 6 7 Mean Plasma Donepezi

  23. Slide 23: Most Common GI Side Effects (Through Week 11)

    Most Common GI* Side Effects (Through Week 11) * GI = Gastrointestinal 0 1 2 4 5 2 2 3 10 3 4 7 0 2 4 6 8 10 12 Nausea Vomiting Diarrhea Constipation Number of Subjects Reporting Adverse Reaction GI - Related Adverse Reactions, by Subject Count (out of total 20 per treatment arm) Patch A Patch B Ora

  24. Slide 24: Favorable Skin Tolerability

    Favorable Skin Tolerability 38 * Score on a rating scale of 0 (none) to 7 (strong reaction beyond test site) per FDA draft guidance on dermal response Number of subjects exhibiting no irritation (Score of 0) are not displayed in chart above 6 3 3 2 2 1 0 5 10 15 20 25 30 35 Day One Day Two Day Three

  25. Slide 25: Parallel Pathways to Commercialization

    Parallel Pathways to Commercialization 2016 2017 2018 2019 2020 2021 Pilot BE IND Pivotal BE File NDA Commercialize Donepezil Memantine Pilot BE IND Pivotal BE File NDA Commercialize Prep PK Wear

  26. Slide 26: Compelling Momentum in Alzheimer's Programs

    Compelling Momentum in Alzheimer’s Programs Products delivering two most widely prescribed drugs Pursuing streamlined development path Early data in Donepezil pilot is promising Potential approval 2019 Memantine following closely Demonstrated market value; reimbursement comparable to Exelon patch Ve

  27. Slide 27: Advancing Proprietary and Partnered Pipelines

    Clonidine TDS Hypertension Marketed Fentanyl TDS Pain Marketed Crest® Whitestrips (5 Products) Teeth Whitening Marketed Twirla® Contraception Phase 3 Undisclosed Motion Sickness ANDA filed Aripiprazole Schizophrenia Phase 1 Corium Corplex Donepezil Alzheimer’s Disease Pilot BE Corium Corplex Memanti

  28. Slide 28: Twirla Product Co-development Program

    Twirla Product Co-development Program Future revenue growth driver Agile (AGRX) contraceptive patch Exclusive manufacturer Delivers low dose of contraceptive hormones Agile indicating potential approval 2H 2017

  29. Slide 29: Product Concept to Commercialization

    Product Concept to Commercialization Commercial Manufacturing R&D Operations Grand Rapids, Michigan Corplex scale-up and clinical production Turnkey facilities for Agile/Corplex CNS San Francisco Bay Area Corplex and MicroCor feasibility MicroCor clinical production (Phase 1/2a) ~ 210 Employees as o

  30. Slide 30: Financial Highlights at September 30, 2016

    FY2016 total revenues of $33M Sole supplier of Crest Whitestrips for P&G $39.8M in unrestricted cash $51M in long term debt (due June 2019) FY2016 average burn of $8.1M/quarter 22.4M shares outstanding 42% shareholder: Essex Woodlands Financial Highlights at September 30, 2016

  31. Slide 31: Advancing Pipeline with Near-term Milestones

    CY 2017 CY 2018 1H 2H 1H 2H Results of Pilot BE study on donepezil Pivotal BE study on donepezil PK results on optimized memantine Pilot BE study on memantine Twirla resubmission* Twirla NDA response* Advancing Pipeline with Near-term Milestones 3Q CY 2017 1H CY 2017 Data 1H CY 2017 Anticipating 6-M

  32. Slide 32: Corium: Growth and Momentum in 2017

    High-value CNS pipeline opportunity and strong IP Corplex Memantine as fast follow-on in Alzheimer’s Parkinson’s, migraine, and pain to expand CNS specialty franchise Corium: Growth and Momentum in 2017 Building on 10+ years of development and commercial manufacturing Twirla to drive growth in partn

  33. Slide 33: Thank You

    Thank You Nasdaq: CORI January 2017 Corium

Corium International — Investor Presentation (January 2017) on 6ix